| Literature DB >> 30362511 |
AmirReza Hesari1, Mitra Azizian2, Alireza Sheikhi3, Abolfazl Nesaei4, Shahin Sanaei5, Nazanin Mahinparvar5, Maryam Derakhshani6, Pegah Hedayt6, Faezeh Ghasemi7, Hamed Mirzaei8.
Abstract
Esophageal cancer is a common malignant tumor with an increasing trend during the past three decades. Currently, esophagectomy, often in combination with neoadjuvant chemo- and radiotherapy, is the cornerstone of curative treatment for esophageal cancer. However, esophagostomy is related to significant risks of perioperative mortality and morbidity, as well as lengthy recovery. Moreover, the adjuvant therapies including chemotherapy and radiotherapy are associated with numerous side effects, limiting compliance and outcome. The dietary agent curcumin has been extensively studied over the past few decades and is known to have many biological activities especially in regard to the prevention and potential treatment of cancer. This review summarizes the chemo-preventive and chemotherapeutic potential of curcumin in esophageal cancer in both preclinical and clinical settings.Entities:
Keywords: MicroRNA; clinical trials; curcumin; esophageal cancer; therapy
Mesh:
Substances:
Year: 2018 PMID: 30362511 DOI: 10.1002/ijc.31947
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396